PRMT5 and adult T-cell leukemia/lymphoma: Furthermore, selective inhibition of PRMT5 by a novel small molecule inhibitor (PRMT5i) in HTLV-1-positive cell lines reduced cell survival; therefore, PRMT5 may represent an important therapeutic target for ATLL.